290 related articles for article (PubMed ID: 27067974)
1. Microparticles and cancer thrombosis in animal models.
Mege D; Mezouar S; Dignat-George F; Panicot-Dubois L; Dubois C
Thromb Res; 2016 Apr; 140 Suppl 1():S21-6. PubMed ID: 27067974
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo.
Mezouar S; Darbousset R; Dignat-George F; Panicot-Dubois L; Dubois C
Int J Cancer; 2015 Jan; 136(2):462-75. PubMed ID: 24889539
[TBL] [Abstract][Full Text] [Related]
3. Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism.
Campello E; Spiezia L; Radu CM; Bulato C; Castelli M; Gavasso S; Simioni P
Thromb Res; 2011 May; 127(5):473-7. PubMed ID: 21256535
[TBL] [Abstract][Full Text] [Related]
4. Tissue factor-bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer.
Date K; Ettelaie C; Maraveyas A
J Thromb Haemost; 2017 Dec; 15(12):2289-2299. PubMed ID: 29028284
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulants versus cancer.
Tieken C; Versteeg HH
Thromb Res; 2016 Apr; 140 Suppl 1():S148-53. PubMed ID: 27067969
[TBL] [Abstract][Full Text] [Related]
6. Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role.
Sartori MT; Della Puppa A; Ballin A; Campello E; Radu CM; Saggiorato G; d'Avella D; Scienza R; Cella G; Simioni P
Thromb Haemost; 2013 Aug; 110(2):378-85. PubMed ID: 23803674
[TBL] [Abstract][Full Text] [Related]
7. Microparticles in vascular disorders: how tissue factor-exposing vesicles contribute to pathology and physiology.
Kleinjan A; Böing AN; Sturk A; Nieuwland R
Thromb Res; 2012 Oct; 130 Suppl 1():S71-3. PubMed ID: 23026670
[TBL] [Abstract][Full Text] [Related]
8. Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study.
van Doormaal F; Kleinjan A; Berckmans RJ; Mackman N; Manly D; Kamphuisen PW; Richel DJ; Büller HR; Sturk A; Nieuwland R
Thromb Haemost; 2012 Jul; 108(1):160-5. PubMed ID: 22535219
[TBL] [Abstract][Full Text] [Related]
9. Microparticles reveal cell activation during IVF - a possible early marker of a prothrombotic state during the first trimester.
Olausson N; Mobarrez F; Wallen H; Westerlund E; Hovatta O; Henriksson P
Thromb Haemost; 2016 Aug; 116(3):517-23. PubMed ID: 27412479
[TBL] [Abstract][Full Text] [Related]
10. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients.
Geddings JE; Mackman N
Blood; 2013 Sep; 122(11):1873-80. PubMed ID: 23798713
[TBL] [Abstract][Full Text] [Related]
11. Tumour and microparticle tissue factor expression and cancer thrombosis.
Date K; Hall J; Greenman J; Maraveyas A; Madden LA
Thromb Res; 2013 Feb; 131(2):109-15. PubMed ID: 23237339
[TBL] [Abstract][Full Text] [Related]
12. Effects of tumor-expressed coagulation factors on cancer progression and venous thrombosis: is there a key factor?
Ünlü B; Versteeg HH
Thromb Res; 2014 May; 133 Suppl 2():S76-84. PubMed ID: 24862150
[TBL] [Abstract][Full Text] [Related]
13. Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice.
Thomas GM; Brill A; Mezouar S; Crescence L; Gallant M; Dubois C; Wagner DD
J Thromb Haemost; 2015 Jul; 13(7):1310-9. PubMed ID: 25955268
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of circulating microparticles for venous thromboembolism in cancer patients.
Thaler J; Ay C; Pabinger I
Hamostaseologie; 2012; 32(2):127-31. PubMed ID: 21792463
[TBL] [Abstract][Full Text] [Related]
15. Tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients.
Hernández C; Orbe J; Roncal C; Alvarez-Hernandez M; Martinez de Lizarrondo S; Alves MT; García Mata J; Páramo JA
Thromb Haemost; 2013 Sep; 110(3):598-608. PubMed ID: 23803792
[TBL] [Abstract][Full Text] [Related]
16. Measurement of microparticle tissue factor activity in clinical samples: A summary of two tissue factor-dependent FXa generation assays.
Hisada Y; Alexander W; Kasthuri R; Voorhees P; Mobarrez F; Taylor A; McNamara C; Wallen H; Witkowski M; Key NS; Rauch U; Mackman N
Thromb Res; 2016 Mar; 139():90-7. PubMed ID: 26916302
[TBL] [Abstract][Full Text] [Related]
17. Cancer and thrombosis in women - molecular mechanisms.
Rickles FR
Thromb Res; 2009; 123 Suppl 2():S16-20. PubMed ID: 19217469
[TBL] [Abstract][Full Text] [Related]
18. Microparticles as biomarkers of venous thromboembolic events.
Campello E; Spiezia L; Radu CM; Simioni P
Biomark Med; 2016 Jul; 10(7):743-55. PubMed ID: 27338783
[TBL] [Abstract][Full Text] [Related]
19. The polyphosphate/factor XII pathway in cancer-associated thrombosis: novel perspectives for safe anticoagulation in patients with malignancies.
Nickel KF; Labberton L; Long AT; Langer F; Fuchs TA; Stavrou EX; Butler LM; Renné T
Thromb Res; 2016 May; 141 Suppl 2():S4-7. PubMed ID: 27207422
[TBL] [Abstract][Full Text] [Related]
20. Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism.
Manly DA; Wang J; Glover SL; Kasthuri R; Liebman HA; Key NS; Mackman N
Thromb Res; 2010 Jun; 125(6):511-2. PubMed ID: 19854471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
